
Quiz: How COLUMBUS Study Results Impact Skin Cancer Treatment
How much do you know about the COLUMBUS study? Test your knowledge of the phase III trial with our latest quiz.
Question 1
Answer
C.55,500
Around the world an
Question 2
Answer
D.All of the above
Normal lactate dehydrogenase concentrations, metastasis
Question 3
Answer
D.All of the above
While the US Food and Drug Administration (FDA) has
Question 4
Answer
C.33.6 months
The small-molecule BRAF kinase inhibitor encorafenib plus the selective MEK inhibitor binimetinib were tolerable and yielded a median overall survival
Question 5
Answer
A.Elevated gamma-glutamyl transpeptidase (GGT)
In the COLUMBUS
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.